Scientific Library

The Blood-Brain Barrier (BBB) affects the development of drugs for all pathologies (brain exposure to drugs, side effects...). In the early phases of drug development, there is a strong need for stable

Protein Gene Product 9.5 (PGP 9.5) is an abundant cytoplasmic neuron and neuroendocrine-cell specific protein. Over the years, this deubiquitinating enzyme (a.k.a. Ubiquitin Carboxy-terminal Hydrolase